Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Grinfeld J, Nangalia J, Green AR.

Haematologica. 2017 Jan;102(1):7-17. doi: 10.3324/haematol.2014.113845. Review.

2.

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.

Clara JA, Sallman DA, Padron E.

Cancer Biol Med. 2016 Sep;13(3):360-372.

3.

Long-term serial xenotransplantation of juvenile myelomonocytic leukemia recapitulates human disease in Rag2-/-γc-/- mice.

Krombholz CF, Aumann K, Kollek M, Bertele D, Fluhr S, Kunze M, Niemeyer CM, Flotho C, Erlacher M.

Haematologica. 2016 May;101(5):597-606. doi: 10.3324/haematol.2015.138545.

4.

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.

Liu YL, Yan Y, Webster C, Shao L, Lensing SY, Ni H, Feng W, Colorado N, Pathak R, Xiang Z, Hauer-Jensen M, Li S, Zhou D, Emanuel PD.

Blood. 2016 Apr 14;127(15):1912-22. doi: 10.1182/blood-2015-05-646216.

5.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

6.

Peripheral blood cells from children with RASopathies show enhanced spontaneous colonies growth in vitro and hyperactive RAS signaling.

Gaipa G, Bugarin C, Cianci P, Sarno J, Bonaccorso P, Biondi A, Selicorni A.

Blood Cancer J. 2015 Jul 17;5:e324. doi: 10.1038/bcj.2015.52.

7.

Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity.

Burmeister BT, Wang L, Gold MG, Skidgel RA, O'Bryan JP, Carnegie GK.

J Biol Chem. 2015 May 8;290(19):12058-67. doi: 10.1074/jbc.M115.642983.

8.

Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.

Kratz CP, Franke L, Peters H, Kohlschmidt N, Kazmierczak B, Finckh U, Bier A, Eichhorn B, Blank C, Kraus C, Kohlhase J, Pauli S, Wildhardt G, Kutsche K, Auber B, Christmann A, Bachmann N, Mitter D, Cremer FW, Mayer K, Daumer-Haas C, Nevinny-Stickel-Hinzpeter C, Oeffner F, Schlüter G, Gencik M, Überlacker B, Lissewski C, Schanze I, Greene MH, Spix C, Zenker M.

Br J Cancer. 2015 Apr 14;112(8):1392-7. doi: 10.1038/bjc.2015.75.

9.

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A.

Haematologica. 2015 Jan;100(1):17-22. doi: 10.3324/haematol.2014.109892.

10.

RAS diseases in children.

Niemeyer CM.

Haematologica. 2014 Nov;99(11):1653-62. doi: 10.3324/haematol.2014.114595. Review.

11.

Therapeutic potential of targeting the oncogenic SHP2 phosphatase.

Zeng LF, Zhang RY, Yu ZH, Li S, Wu L, Gunawan AM, Lane BS, Mali RS, Li X, Chan RJ, Kapur R, Wells CD, Zhang ZY.

J Med Chem. 2014 Aug 14;57(15):6594-609. doi: 10.1021/jm5006176.

12.

Protein tyrosine phosphatases as wardens of STAT signaling.

Böhmer FD, Friedrich K.

JAKSTAT. 2014 Jan 1;3(1):e28087. doi: 10.4161/jkst.28087. Review.

13.

Noonan syndrome.

Bhambhani V, Muenke M.

Am Fam Physician. 2014 Jan 1;89(1):37-43.

14.

Genetic predispositions to childhood leukemia.

Stieglitz E, Loh ML.

Ther Adv Hematol. 2013 Aug;4(4):270-90. doi: 10.1177/2040620713498161.

16.

Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.

Timeus F, Crescenzio N, Baldassarre G, Doria A, Vallero S, Foglia L, Pagliano S, Rossi C, Silengo MC, Ramenghi U, Fagioli F, Cordero di Montezemolo L, Ferrero GB.

Oncol Rep. 2013 Aug;30(2):553-9. doi: 10.3892/or.2013.2535.

17.
18.

The genomic landscape of hypodiploid acute lymphoblastic leukemia.

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG.

Nat Genet. 2013 Mar;45(3):242-52. doi: 10.1038/ng.2532.

19.

New Genetic Insights into Congenital Heart Disease.

Ware SM, Jefferies JL.

J Clin Exp Cardiolog. 2012 Jun 15;S8. pii: 003.

20.

Severe congenital thrombocytopaenia--first clinical manifestation of Noonan syndrome.

Nunes P, Aguilar S, Prado SN, Palaré MJ, Ferrão A, Morais A.

BMJ Case Rep. 2012 Mar 20;2012. pii: bcr1020114940. doi: 10.1136/bcr.10.2011.4940.

Supplemental Content

Support Center